23 May 2018 - Given all of the recent rhetoric about drug pricing emanating from Washington, one would think that the cost of new drugs continues to soar. 

Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. Such a policy would be fraught with issues as pointed out by Robert Pear in the New York Times. 

But, the decisions that go into the pricing of a new drug are involved and complicated. Is it reasonable to expect the public to understand whether a drug is appropriately priced be it $10/pill or $200,000/year?

Read Forbes Magazine article